Liver Transplant CGM
Post-discharge Glycemic Control After Liver Transplant and Impact on Transplant Outcomes
1 other identifier
observational
40
1 country
1
Brief Summary
This investigator initiated study aims to describe continuous glucose monitoring (CGM) based glycemic metrics after discharge from liver transplant and assess relationship with glycemic metrics and liver transplant outcomes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Oct 2025
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 9, 2025
CompletedStudy Start
First participant enrolled
October 13, 2025
CompletedFirst Posted
Study publicly available on registry
October 14, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 5, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
October 5, 2027
November 12, 2025
November 1, 2025
12 months
October 9, 2025
November 10, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Time in range
Time in range 70-180mg/dL
28 days
Secondary Outcomes (5)
Percent time >180mg/dL
28 days
Percent time >250mg/dL
28 days
Percent time <70mg/dL
28 days
Percent time <54mg/dL
28 days
Transplant outcomes
1 year
Study Arms (1)
Participants post liver transplant
Participants who are discharged from after liver transplant.
Interventions
Blinded CGM will be worn by all participants
Eligibility Criteria
inpatient liver transplant participants who have had an inpatient glucose greater than 180mg/dL
You may qualify if:
- inpatient liver transplant participants who have had an inpatient glucose greater than 180mg/dL
You may not qualify if:
- having a planned discharge to a rehabilitation or nursing facility,
- a contraindication to sensor placement,
- if discharge is anticipated to be \>30 days post-transplant, or
- if recent transplant also included a kidney or pancreas transplant
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Mount Sinai Hospital
New York, New York, 10029, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Grenye O'Malley, MD
Icahn School of Medicine at Mount Sinai
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
October 9, 2025
First Posted
October 14, 2025
Study Start
October 13, 2025
Primary Completion (Estimated)
October 5, 2026
Study Completion (Estimated)
October 5, 2027
Last Updated
November 12, 2025
Record last verified: 2025-11
Data Sharing
- IPD Sharing
- Will not share
Identifying dates